Cardiovascular Protection against Chemotherapeutics and Environmental Toxins: New Agents and Molecular Targets

A special issue of Diseases (ISSN 2079-9721). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 4687

Special Issue Editors


E-Mail
Guest Editor
BIDMC Cardiology, Harvard Medical School, Boston, MA, USA
Interests: cardiovascular pharmacology; cardio-Oncology; molecular medicine
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Chemistry Department, Faculty of Science, Suez Canal University, Ismailia 41522, Egypt
2. Institute for Chemistry, Humboldt Universität zu Berlin, Brook-Taylor-Str. 2, 12489 Berlin, Germany
Interests: synthetic organic chemistry; synthetic medicinal chemistry; stereochemistry; Heterocyclic Chemistry; drug synthesis and development; small molecule drug discovery by high-throughput library screening; computer aided drug design (modelling, virtual screening); chemistry of lipids; role of lipids in human diseases; development of biochemical tools to study structure and function of lipids; development of enzymatic assays
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
Great Plains Health, Callahan Cancer Center, North Platte, NE, USA
Interests: cardiology; cardio-oncology; cardiac imaging
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
Cleveland Clinic Foundation, Cleveland, OH, USA
Interests: ischemia/reperfusion injury; myocardial infarction; cardiomyopathy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Department of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, P.O. Box 6231, Jeddah 21442, Saudi Arabia
2. Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt
Interests: pharmacology; drug toxicology; alternative medicine; environmental pharmacology and toxicology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The characterization, management, and prevention of cardiotoxicity, whether caused by pharmacological agents (cardiovascular and non-cardiovascular) or environmental exposures, compose a growing area of research. Cancer chemotherapeutics, in particular, have multiple off-target effects on the cardiovascular system, and studying these effects has led to the birth of the new cardio-oncology field. This Special Issue aims to present the latest advances in the study of cardiotoxicity and especially the field of cardio-oncology, in order to better understand the underlying mechanisms and improve the cardiac safety of therapeutic interventions. Potential topics include, but are not limited to:

  • Cardiac effects, molecular mechanisms, and signaling pathways of drugs, xenobiotics, and environmental toxins
  • Cardiovascular effects of classic cancer chemotherapeutics (e.g., anthracyclines) and new agents (e.g., immune checkpoint inhibitors)
  • Safety and efficacy of novel cardioprotective agents against cardiotoxicity
  • Development and validation of in vivo and in vitro models to study cardiotoxicity

You may choose our Joint Special Issue in Molecules.

Dr. Abdelrahman I. Abushouk
Dr. Essa Saied
Dr. Kartik Anand
Dr. Anas Saad
Dr. Mohamed M. Abdel-Daim
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiotoxicity
  • cardioprotection
  • cardio-oncology
  • cardiovascular pharmacology
  • molecular cardiology

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 1637 KiB  
Review
Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management
by Ethan A. Burns, Cesar Gentille, Barry Trachtenberg, Sai Ravi Pingali and Kartik Anand
Diseases 2021, 9(1), 20; https://doi.org/10.3390/diseases9010020 - 17 Mar 2021
Cited by 19 | Viewed by 3972
Abstract
Chimeric antigen receptor T-cells (CAR-T) are improving outcomes in pediatric and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemias and subtypes of non-Hodgkin Lymphoma. As this treatment is being increasingly utilized, a better understanding of the unique toxicities associated with this [...] Read more.
Chimeric antigen receptor T-cells (CAR-T) are improving outcomes in pediatric and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemias and subtypes of non-Hodgkin Lymphoma. As this treatment is being increasingly utilized, a better understanding of the unique toxicities associated with this therapy is warranted. While there is growing knowledge on the diagnosis and treatment of cytokine release syndrome (CRS), relatively little is known about the associated cardiac events that occur with CRS that may result in prolonged length of hospital stay, admission to the intensive care unit for pressor support, or cardiac death. This review focuses on the various manifestations of cardiotoxicity, potential risk factors, real world and clinical trial data on prevalence of reported cardiotoxicity events, and treatment recommendations. Full article
Show Figures

Figure 1

Back to TopTop